BR112013014360A2 - método para detectar um alvo em uma amostra mediante deposição de modo proximal de um marcador, composição para detectar um alvo em uma amostra mediante deposição de modo proximal de um marcador e kit que compreende uma solução de detecção - Google Patents
método para detectar um alvo em uma amostra mediante deposição de modo proximal de um marcador, composição para detectar um alvo em uma amostra mediante deposição de modo proximal de um marcador e kit que compreende uma solução de detecçãoInfo
- Publication number
- BR112013014360A2 BR112013014360A2 BR112013014360A BR112013014360A BR112013014360A2 BR 112013014360 A2 BR112013014360 A2 BR 112013014360A2 BR 112013014360 A BR112013014360 A BR 112013014360A BR 112013014360 A BR112013014360 A BR 112013014360A BR 112013014360 A2 BR112013014360 A2 BR 112013014360A2
- Authority
- BR
- Brazil
- Prior art keywords
- marker
- sample
- target
- detecting
- proximally
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
método para detectar um alvo em uma amostra mediante deposição de modo proximal de um marcador, composição para detectar um alvo em uma amostra mediante deposição de modo proximal de um marcador e kit que compreende uma solução de detecção esta descrição refere-se a composições que realçam a deposição de porções químicas detectáveis em amostras de tecido, sendo que os métodos utilizam essas composições e kits que incluem essas composições. as composições incluem um realçador de deposição que tem uma fórmula e/ou em que r^ 1^, r^ 2^, r^ 3^ e r^ 4^ são independetemente selecionados dentre uma porção química que contém heteroátomo, alifática, arila, halogênio e hidrogênio; r^ 1^ e/ou r^ 3^ podem ser ligados a r^ 2^ para formar um sistema de anel aromático fundido; r^ 5^ é selecionado dentre uma porção química que contém heteroátomo; a é selecionado dentre um átomo de carbono, um heteroátomo, exceto enxofre, e qualquer combinação dos mesmos; n é 1 a 5, uma enzima, uma porção química de ligação específica e uma porção química detectável.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061460349P | 2010-12-30 | 2010-12-30 | |
| US61/460,349 | 2010-12-30 | ||
| PCT/US2011/067481 WO2012092322A1 (en) | 2010-12-30 | 2011-12-28 | Enhanced deposition of chromogens utilizing pyrimidine analogs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112013014360A2 true BR112013014360A2 (pt) | 2016-10-04 |
| BR112013014360B1 BR112013014360B1 (pt) | 2020-10-13 |
| BR112013014360B8 BR112013014360B8 (pt) | 2020-12-15 |
Family
ID=45554795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013014360A BR112013014360B8 (pt) | 2010-12-30 | 2011-12-28 | método para detectar um alvo em uma amostra e kit |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8871442B2 (pt) |
| EP (2) | EP2659000B1 (pt) |
| JP (2) | JP5815046B2 (pt) |
| KR (1) | KR101554795B1 (pt) |
| CN (1) | CN103282516B (pt) |
| AU (2) | AU2011352251B2 (pt) |
| BR (1) | BR112013014360B8 (pt) |
| CA (2) | CA2817374C (pt) |
| DK (2) | DK3088534T3 (pt) |
| ES (2) | ES2689593T3 (pt) |
| HK (1) | HK1185634A1 (pt) |
| IL (1) | IL226479A (pt) |
| SG (2) | SG190892A1 (pt) |
| WO (1) | WO2012092322A1 (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2659000B1 (en) * | 2010-12-30 | 2016-08-10 | Ventana Medical Systems, Inc. | Enhanced deposition of chromogens utilizing pyrimidine analogs |
| WO2013110549A1 (en) | 2012-01-23 | 2013-08-01 | Ventana Medical Systems, Inc. | Polymer stabilization of chromogen solutions |
| ES2678211T3 (es) | 2012-03-27 | 2018-08-09 | Ventana Medical Systems, Inc. | Conjugados de señalización y procedimientos de uso |
| CN104603620B (zh) | 2012-09-24 | 2018-02-23 | 文塔纳医疗系统公司 | 使用间变性淋巴瘤激酶(alk)作为标志物鉴定治疗响应性非小细胞肺癌的方法 |
| RU2662681C2 (ru) * | 2013-02-28 | 2018-07-26 | Нитирей Байосайенсиз Инк. | Набор даб-содержащего субстрата для окрашивания, производимого ферментом для мечения |
| CA2900842C (en) | 2013-03-12 | 2020-01-21 | Ventana Medical Systems, Inc. | Digitally enhanced microscopy for multiplexed histology |
| US9689875B2 (en) | 2013-08-28 | 2017-06-27 | Ventana Medical Systems, Inc. | Immunohistochemical assay for detection of CD3 and CD16 |
| AU2015220750B2 (en) | 2014-02-24 | 2020-04-16 | Ventana Medical Systems, Inc. | Quinone methide analog signal amplification |
| JP6880001B2 (ja) | 2015-08-28 | 2021-06-02 | ヴェンタナ メディカル システムズ， インク． | ケージドハプテンを使用するホルマリン固定パラフィン包埋組織におけるタンパク質近接アッセイ |
| US10718694B2 (en) * | 2016-04-18 | 2020-07-21 | Diagnostic Biosystems | Counterstains for a biological sample |
| EP3475291A1 (en) | 2016-06-28 | 2019-05-01 | Ventana Medical Systems, Inc. | Application of click chemistry for signal amplification in ihc and ish assays |
| EP3475701B1 (en) | 2016-06-28 | 2023-02-22 | Ventana Medical Systems, Inc. | New colors for chromogenic ihc and ish staining with multi-dye quinone methide and tyramide conjugates |
| WO2019002281A1 (en) | 2017-06-28 | 2019-01-03 | Ventana Medical Systems, Inc. | CALIBRATION OF SYSTEM LEVEL |
| WO2020058339A1 (en) | 2018-09-20 | 2020-03-26 | Ventana Medical Systems, Inc. | Coumarin-based crosslinking reagents |
| JP2020071152A (ja) | 2018-10-31 | 2020-05-07 | ソニー株式会社 | 免疫染色方法、免疫染色システム、および免疫染色キット |
| JP2023538753A (ja) | 2020-08-28 | 2023-09-11 | ヴェンタナ メディカル システムズ， インク． | 検出可能な部分を含むコンジュゲート |
| CN116710131A (zh) | 2020-09-22 | 2023-09-05 | 文塔纳医疗系统公司 | 使用表皮调节素和双调蛋白来预测对表皮生长因子受体定向疗法的反应 |
| EP4278181A1 (en) | 2021-01-15 | 2023-11-22 | Ventana Medical Systems, Inc. | Storage stable caged haptens |
| EP4281779A1 (en) | 2021-01-25 | 2023-11-29 | Ventana Medical Systems, Inc. | Stained biological specimens including one or more biomarkers labeled with one or more detectable moieties |
| JP2024516380A (ja) | 2021-04-18 | 2024-04-15 | ヴェンタナ メディカル システムズ， インク． | 形態学的マーカー染色 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1564604A (en) | 1925-06-12 | 1925-12-08 | Chas S Hodges | Water wheel |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4318984A (en) * | 1979-11-13 | 1982-03-09 | Miles Laboratories, Inc. | Stabilized composition, test device, and method for detecting the presence of a sugar in a test sample |
| GB8713951D0 (en) * | 1987-06-15 | 1987-07-22 | Dewar M H | Enhanced chemiluminescent reaction |
| WO1990003370A1 (en) * | 1988-09-28 | 1990-04-05 | Microprobe Corporation | DERIVATIVES OF PYRAZOLO[3,4-d]PYRIMIDINE |
| US5225325A (en) | 1990-03-02 | 1993-07-06 | Ventana Medical Systems, Inc. | Immunohistochemical staining method and reagents therefor |
| US5595707A (en) | 1990-03-02 | 1997-01-21 | Ventana Medical Systems, Inc. | Automated biological reaction apparatus |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| DK0656946T4 (da) | 1992-08-21 | 2010-07-26 | Univ Bruxelles | Immunoglobuliner uden lette kæder |
| GB9306888D0 (en) * | 1993-04-01 | 1993-05-26 | Kricka Larry J | Chemiluminescent enhancers |
| JPH07308200A (ja) * | 1994-05-16 | 1995-11-28 | Konica Corp | ペルオキシダーゼ様物質の活性または酸化性物質の検出及び測定のための組成物並びに測定方法 |
| KR0164072B1 (ko) | 1995-11-13 | 1999-02-01 | 김주용 | 반도체 소자의 얕은 접합 형성방법 |
| US6316228B1 (en) * | 1996-10-21 | 2001-11-13 | The University Of Iowa Research Foundation | Efficient synthesis of nucleosides |
| US5866366A (en) | 1997-07-01 | 1999-02-02 | Smithkline Beecham Corporation | gidB |
| US20030211630A1 (en) | 1998-02-27 | 2003-11-13 | Ventana Medical Systems, Inc. | Automated molecular pathology apparatus having independent slide heaters |
| US6582962B1 (en) | 1998-02-27 | 2003-06-24 | Ventana Medical Systems, Inc. | Automated molecular pathology apparatus having independent slide heaters |
| US6296809B1 (en) | 1998-02-27 | 2001-10-02 | Ventana Medical Systems, Inc. | Automated molecular pathology apparatus having independent slide heaters |
| DE19834938C2 (de) * | 1998-07-29 | 2000-07-20 | Coty Bv | Verfahren zur kosmetischen Bräunungsbestimmung einer Selbstbräunungszusammensetzung und Test-Kit |
| US6372937B1 (en) | 1998-11-09 | 2002-04-16 | Mark Norman Bobrow | Enhanced catalyzed reporter deposition |
| US6355443B1 (en) * | 1999-03-17 | 2002-03-12 | Mark Norman Bobrow | 4-(4-hydroxystyryl) pyridine-containing substrates for an analyte dependent enzyme activation system |
| US6649138B2 (en) | 2000-10-13 | 2003-11-18 | Quantum Dot Corporation | Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media |
| US20020076732A1 (en) * | 2000-12-15 | 2002-06-20 | Kaplan David R. | Methods for detecting an analyte of interest using catalyzed reporter deposition of tyramide |
| US20020083888A1 (en) | 2000-12-28 | 2002-07-04 | Zehnder Donald A. | Flow synthesis of quantum dot nanocrystals |
| US6670113B2 (en) | 2001-03-30 | 2003-12-30 | Nanoprobes | Enzymatic deposition and alteration of metals |
| US6617125B2 (en) * | 2001-06-29 | 2003-09-09 | Perkinelmer Life Sciences, Inc. | Compositions for enhanced catalyzed reporter deposition |
| CA2453450A1 (en) | 2001-07-20 | 2003-11-06 | Quantum Dot Corporation | Luminescent nanoparticles and methods for their preparation |
| US7642064B2 (en) | 2003-06-24 | 2010-01-05 | Ventana Medical Systems, Inc. | Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest |
| DK1636586T3 (da) | 2003-06-24 | 2009-11-23 | Ventana Med Syst Inc | Enzymkatalyseret metaldeponering til foröget in situ-detektion af immunhistokemisker epitoper og nucleinsyresekvenser |
| EP2659000B1 (en) * | 2010-12-30 | 2016-08-10 | Ventana Medical Systems, Inc. | Enhanced deposition of chromogens utilizing pyrimidine analogs |
-
2011
- 2011-12-28 EP EP11813853.6A patent/EP2659000B1/en active Active
- 2011-12-28 DK DK16161377.3T patent/DK3088534T3/en active
- 2011-12-28 BR BR112013014360A patent/BR112013014360B8/pt active IP Right Grant
- 2011-12-28 WO PCT/US2011/067481 patent/WO2012092322A1/en active Application Filing
- 2011-12-28 SG SG2013040589A patent/SG190892A1/en unknown
- 2011-12-28 DK DK11813853.6T patent/DK2659000T3/en active
- 2011-12-28 CN CN201180062801.5A patent/CN103282516B/zh active Active
- 2011-12-28 CA CA2817374A patent/CA2817374C/en active Active
- 2011-12-28 JP JP2013547631A patent/JP5815046B2/ja active Active
- 2011-12-28 US US13/339,066 patent/US8871442B2/en active Active
- 2011-12-28 ES ES16161377.3T patent/ES2689593T3/es active Active
- 2011-12-28 AU AU2011352251A patent/AU2011352251B2/en active Active
- 2011-12-28 SG SG10201804238TA patent/SG10201804238TA/en unknown
- 2011-12-28 ES ES11813853.6T patent/ES2593464T3/es active Active
- 2011-12-28 EP EP16161377.3A patent/EP3088534B1/en active Active
- 2011-12-28 CA CA3007179A patent/CA3007179C/en active Active
- 2011-12-28 KR KR1020137016695A patent/KR101554795B1/ko active IP Right Grant
-
2013
- 2013-05-21 IL IL226479A patent/IL226479A/en active IP Right Grant
- 2013-11-20 HK HK13112956.2A patent/HK1185634A1/xx unknown
-
2014
- 2014-10-06 US US14/507,447 patent/US9435795B2/en active Active
-
2015
- 2015-06-17 JP JP2015122090A patent/JP6130438B2/ja active Active
- 2015-07-30 AU AU2015207891A patent/AU2015207891B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013014360A2 (pt) | método para detectar um alvo em uma amostra mediante deposição de modo proximal de um marcador, composição para detectar um alvo em uma amostra mediante deposição de modo proximal de um marcador e kit que compreende uma solução de detecção | |
| Kong et al. | Islet biology, the CDKN2A/B locus and type 2 diabetes risk | |
| ES2552311T3 (es) | Derivados heterocíclicos | |
| BRPI0613429A2 (pt) | inibidores de histona desacetilase | |
| BRPI0906104B8 (pt) | derivado de ácido peptonucleico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido peptonucleico, método de utilização do derivado de ácido peptonucleico e composto | |
| WO2012080284A3 (en) | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | |
| BR112015012366A8 (pt) | antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido | |
| RU2017100015A (ru) | Набор или устройство для обнаружения рака желчных путей и способ обнаружения | |
| BR112012008939A2 (pt) | processo para a preparação de compostos úteis como inibidores de sglt2 | |
| MX2009005781A (es) | Moleculas indicadoras resistentes a la oxidacion. | |
| BRPI0806789B8 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| BR112012033658A2 (pt) | derivados bipiridílicos úteis para o tratamento de doenças induzidas por quinases | |
| BR112012026147A2 (pt) | espiroderivados azacíclicos como inibidores de hsl | |
| BR112012018954A2 (pt) | derivados de hetaril-[1,8]naftiridina | |
| BRPI0810661A2 (pt) | [2,6] naftiridinas úteis como inibidoras de quinase proteica. | |
| CY1118170T1 (el) | Νεα φωσφινικα οξεα και παραγωγα θειου αυτων και μεθοδοι για την παρασκευη τους | |
| UA105296C2 (ru) | Определение и подсчет микроорганизмов | |
| ECSP099351A (es) | Compuestos heterociclicos y su uso como inhibidores de la | |
| CY1116496T1 (el) | Στεροειδη c-19 για θεραπευτικες χρησεις | |
| Zhu et al. | A detective story in drug discovery: elucidation of a screening artifact reveals polymeric carboxylic acids as potent inhibitors of RNA polymerase. | |
| ATE493110T1 (de) | Kosmetische zusammensetzung zur stimulierung der synthese der proteine der basalmembran | |
| ATE538216T1 (de) | Nukleinsäureverstärkung mithilfe eines reversibel modifizierten oligonukleotids | |
| BR112022010054A2 (pt) | Compostos heterocíclicos como inibidores de delta-5 dessaturase e métodos de uso | |
| BRPI0607016A2 (pt) | marcadores polipeptìdicos para o diagnóstico de cáncer de próstata | |
| Lee et al. | Structure–activity relationship of the 7-hydroxy benzimidazole analogs as glycogen synthase kinase 3β inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/12/2011, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2597 DE 13/10/2020 QUANTO AO RELATORIO DESCRITIVO. |